StockNews.AI
SMMT
StockNews.AI
5 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

1. Pomerantz LLP is investigating Summit Therapeutics for potential securities fraud. 2. SMMT's stock dropped 30.5% after a disappointing drug trial result. 3. Further negative data caused SMMT's stock to fall 25.15% more recently. 4. Investors may join a class action regarding these allegations against SMMT.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The recent significant stock drops indicate strong negative sentiment and investor concerns following trial results.

How important is it?

Ongoing investigations into fraud and significant stock drops will draw heightened investor scrutiny.

Why Short Term?

Immediate investor reactions to ongoing investigations will likely affect stock price shortly.

Related Companies

IBIOGNUS
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 30, 2025, Summit issued a press release “announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]” Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause. On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. Then, on September 7, 2025, Summit announced additional data from the trial, in which ivonescimab produced weaker results in patients from North America and Europe than in those from Europe. On this news, Summit’s stock price fell $6.54 per share, or 25.15%, to close at $19.45 per share on September 8, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News